Already a member?
Login
Become a member
Register
Menu
Home
About Us
About CGRP Forum
Editorial Board
About CGRP
About CGRP
CGRP and migraine
Unmet needs in migraine prevention
What is the role of CGRP in migraine?
Why is CGRP an important therapeutic target?
Migraine is a complex neurovascular condition
News
News
Meeting Reports
Real World Experience
Newsletter
Hot Topics
Videos
Meet the Expert: Issues and Answers
Trials
Atogepant (AGN-241689)
Erenumab (AMG 334)
Eptinezumab (ALD403)
Galcanezumab (LY2951742)
Fremanezumab (TEV-48125)
Rimegepant (BHV-3000)
Ubrogepant (MK-1602)
Resources
CGRP in the Journals
Meetings
Backgrounders
Slides
Links
Videos
Contact US
Hot off the press: New Forum launches
Latest:
Should CGRP mAbs be first-line preventive treatment for migraine?
DELIVER results confirm eptinezumab efficacy across sub-groups
Sustained benefits of erenumab vs oral preventives
Daily headache does not impede response to galcanezumab
Interim PEARL analysis supports real world efficacy of fremanezumab
Further evidence of CGRP rise after mAb treatment
Trigeminal symptoms may predict anti-CGRP mAb response
Eligible patients with migraine still miss out on preventive therapies
Robert Shapiro, M.D.
Robert Shapiro, M.D.
Post navigation
Published in
Robert E Shapiro
Trials
Atogepant (AGN-241689)
Erenumab (AMG 334)
Galcanezumab (LY2951742)
Fremanezumab (TEV-48125)
Eptinezumab (ALD403)
Rimegepant (BHV-3000)
Ubrogepant (MK-1602)
Meeting Reports
8th Congress of the European Academy of Neurology
64th Annual Meeting of the American Headache Society
American Academy of Neurology 2022
XXV World Congress of Neurology 2021
International Headache Congress 2021
7th Congress of the European Academy of Neurology
63rd Annual Meeting of the American Headache Society
American Academy of Neurology 2021 Virtual Annual Meeting
Migraine Trust International Symposium 2020
14th European Headache Federation Congress
62nd Annual Meeting of the American Headache Society
6th Congress of the European Academy of Neurology
American Academy of Neurology 2020
World Congress of Neurology 2019
IHC 2019
American Headache Society (AHS) 61st Annual Scientific Meeting
5th Congress of the European Academy of Neurology
13th European Headache Federation Congress
American Academy of Neurology Annual Meeting 2019
12th European Headache Federation Congress
17th Biennial Migraine Trust International Symposium
American Headache Society (AHS) 60th Annual Scientific Meeting
4th Congress of the European Academy of Neurology
American Academy of Neurology (AAN) Congress
11th European Headache Federation Congress
18th Congress of the International Headache Society
American Headache Society Annual Scientific Meeting
3rd Congress of the European Academy of Neurology
American Academy of Neurology Annual Meeting
Scottsdale Headache Symposium
The European Headache and Migraine Trust International Congress (EHMTIC)
Resources
Slides
Migraine care in Brazil: the role of anti-CGRP therapies
Atogepant
Erenumab
Eptinezumab
Meetings
Links
Invite a colleague »
MENU
Home
About Us
About CGRP Forum
Editorial Board
About CGRP
About CGRP
CGRP and migraine
Unmet needs in migraine prevention
What is the role of CGRP in migraine?
Why is CGRP an important therapeutic target?
Migraine is a complex neurovascular condition
News
News
Meeting Reports
Real World Experience
Newsletter
Hot Topics
Videos
Meet the Expert: Issues and Answers
Trials
Atogepant (AGN-241689)
Erenumab (AMG 334)
Eptinezumab (ALD403)
Galcanezumab (LY2951742)
Fremanezumab (TEV-48125)
Rimegepant (BHV-3000)
Ubrogepant (MK-1602)
Resources
CGRP in the Journals
Meetings
Backgrounders
Slides
Links
Videos
Contact US